Neurology® Podcast

In this special podcast for the Neurology Journal, Dr. Ted M. Burns plays a dozen of the many interesting audio clips from Neurology Podcasts of the 2012-2013 academic year.

In this special Podcast from the Neurology Resident & Fellow (R&F) Section, members of the R&F Editorial team interview some residents who presented posters at the 2013 AAN Annual Meeting in San Diego. Other interesting segments include the Top 10 Ways for Program Directors to the Use the Neurology Resident & Fellow Section and interviews of authors this year's R&F Highlights booklet. The participants had nothing to disclose except Drs. Cahill, Wong, Strowd, Sarkar, Pressman and Clardy.Dr. Cahill serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Wong served on the editorial team for the Neurology® Resident and Fellow Section.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Sarkar received honoraria from the Young Researcher Award from CNS.Dr. Pressman serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Clardy served on the editorial team for the Neurology® Resident and Fellow Section.

1) Evidence-based guideline: Treatment of tardive syndromes and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Waugh interviews Drs. Roongroj Bhidayasiri and Gary Gronseth about the AAN evidence-based guideline on treatment of tardive syndromes. Dr. Roy Strowd is reading our e-Pearl of the week about CTA spot sign. In the next part of the podcast Dr. Alberto Espay interviews Dr. Marsel Mesulam about his H. Houston Merritt Lecture on the selective cognitive impairments and distinct neuropathological entities of the primary progressive aphasias. The participants had nothing to disclose except Drs. Bhidayasiri, Gronseth, Strowd, Espay and Mesulam.Dr. Bhidayasiri served as Editor-in-Chief for The Thai Journal of Neurology; serves on the scientific advisory board for Ministry of Public Heath, Thailand and Excellence Network; serves as Director of Chulalongkorn Center of Excellence on Parkinson's Disease and Related Disorders, Thai Red Cross Society; received funding for trips from BL Hua, GlaxoSmithKline, Medtronic, Inc., Roche; serves on the speakers' bureau of Abbott, BL Hua, Boehringer-Ingelheim, GlaxoSmithKline, Medtronic, Inc., Novartis, Roche; receives royalties from the publication of the books Neurological Differential diagnosis, International Neurology, Movement Disorders: A video atlas; receives research support from Abbott, Immunocal Thailand, Chulalongkorn University, Bangkok, Thailand, Thailand Research Fund and Thai Red Cross Society.Dr. Gronseth serves on the editorial board of Neurology Now and receives research support from the American Academy of Neurology.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Mesulam serves on the scientific advisory board for Cure Alzheimer Fund and Association on Frontotemporal Dementia; serves as an editorial board member of Brain, Annals of Neurology, Human Brain Mapping, Journal of Cognitive Neuroscience; receives royalties from the publication of the book Principles of Behavioral and Cognitive Neurology and receives research support from the NIH.

1) Rasmussen's encephalitis treated with natalizumab and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Prof. Heinz Wiendl about his paper on Rasmussen's encephalitis treated with natalizumab. Dr. Roy Strowd is reading our e-Pearl of the week about watching for Whipple's: Oculomasticatory myorhythmia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Pooja Khatri on intra-arterial therapy being used as standard treatment for acute stroke. The participants had nothing to disclose except Prof. Wiendl, Drs. Strowd, Espay and Khatri.Prof. Wiendl received honoraria for travel to attend meetings from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi- Aventis, Schering-Plough Corp., Merck Serono, Teva Pharmaceuticals Industries Ltd.; has served as a consultant or is currently a consultant for Merck Serono, Medac, Inc, Sanofi-aventis, Biogen Idec, Bayer Schering Pharma, Novartis, Teva Pharmaceuticals Industries Ltd., Novo Nordisk; receives research support from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi-aventis, Merck Serono, Teva Pharmaceuticals Industries Ltd., Novartis, Medac, Inc, Genzyme and Novo Nordisk.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Khatri received funding for a trip from Genetech, Inc.; provided expert witnessing for stroke cases over last two years; receives research support from Penumbra, Inc and the NIH.

1) Development and validation of a clinical guideline for diagnosing blepharospasm and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Giovanni Defazio about his paper on development and validation of a clinical guideline for diagnosing blepharospasm. Dr. Roy Strowd is reading our e-Pearl of the week about iatrogenic botulism. In the next part of the podcast Dr. Alberto Espay interviews Dr. Salvatore DiMauro about his Robert Wartenberg Lecture on Mitochondrial encephalomyopathies: 50 years on. The participants had nothing to disclose except Drs. Defazio, Strowd, Espay and DiMauro.Dr. Defazio receives research support from the Italian Ministry of University and Comitato Promotore Telethon.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. DiMauro serves as an editorial board member of Muscle and Nerve, Neuromuscular Disorders, Acta Myologica, MedLink Neurology; serves on the scientific advisory board for Telethon Italia; receives research support from the Muscular Dystrophy Association, Marriott Mitochondrial Disorder Clinical Research Fund and the NIH.

1) Surveillance neuroimaging and neurologic examinations affecting care for intracerebral hemorrhage and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Dr. Matthew Maas about his paper on surveillance neuroimaging and neurologic examinations affecting care for intracerebral hemorrhage. Dr. Roy Strowd is reading our e-Pearl of the week about dopamine dysregulation syndrome in Parkinson disease. In the next part of the podcast Dr. Alberto Espay interviews Drs. Stephen Reich and C. Warren Olanow on levodopa being initiated at time of diagnosis of movement disorders. The participants had nothing to disclose except Drs. Maas, Strowd, Espay, Olanow and Reich.Dr. Maas receives research support from the NIH.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Olanow serves as Chief Editor for Movement Disorders; serves on the scientific advisory board for Michael J. Fox Foundation, TEVA Pharmaceutical Industries Ltd, Ceregene; is a consultant for TEVA Pharmaceutical Industries Ltd, Lundbeck, Inc., Novartis, Impax Pharmaceuticals, Ceregene, Orion; holds stock options in Ceregene and Clintrex, receives research support from Ceregene and participated in legal proceedings involving welding defense.Dr. Reich receives royalties from the publication of the book Movement Disorders: 100 Instructive Cases; receives research support from Chiltern, Synosia pharmaceuticals, Phytopharm and the NIH.

1) Depressive symptoms and white matter dysfunction in retired NFL players with concussion history and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Christopher Giza interviews Dr. John Hart about his paper on depressive symptoms and white matter dysfunction in retired NFL players. Dr. Adam Numis is reading our e-Pearl of the week about ice-cream headache. In the next part of the podcast Dr. Alberto Espay interviews Drs. Ron Postuma and Brad Boeve about clinicopathologic correlations in 172 cases of REM sleep behavior disorder. The participants had nothing to disclose except Drs. Giza, Hart, Numis, Espay, Postuma and Boeve.Dr. Giza serves on the data safety monitoring board for LAbiomed Institute at Harbor-UCLA Medical Center; is a consult for NHL Player's Association; serves on the speakers' bureau for the Medical Education Speakers Network; receives royalties from the publication of the book Neurological Differential Diagnosis: A prioritized approach; received funding for travel to Major League Soccer Concussion Committee meeting, California State Athletic Commission Meetings and NCAA meeting; receives research funding from NIH, UCLA faculty grants, Thrasher Research Foundation, NFL Charities, Today's and Tomorrow's Children Fund, Richie's Fund and NCAA, and gave expert testimony on several mediocolegal cases.Dr. Hart serves as an editorial board member of Neurocase, Journal of Innovative Optical Health, World Journals of Radiology and Psychiatry, Frontiers in Neuropsychiatric Imaging and Stimulation; receives royalties from the publication of the book Neural Basis of Semantic Memory; receives research support from the Department of Defense, Alzheimer's Association, RGK Foundation and NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Postuma serves on the scientific advisory board for TEVA Pharmaceutical Industries Ltd; serves as an editorial board member of Movement Disorders Journal and Journal of Caffeine Research; receives honoraria from Allergan, Inc., Novartis, TEVA Pharmaceutical Industries Ltd; receives research support from the Canadian Institute of Health Research, Parkinson Society of Canada, Fonds de Recherche de la Sante Quebec, Weston Foundation and Drummond Foundation.Dr. Boeve has served as an investigator for clinical trials sponsored by Cephalon, Inc., Allon Pharmaceuticals and GE Healthcare; receives royalties from the publication of a book Behavioral Neurology of Dementia; received honoraria from the American Academy of Neurology; serves on the scientific advisory board of the Tau Consortium and receives research support from the National Institute on Aging and the Mangurian Foundation.

Stroke Update 2013

1) Guideline update: Evaluation and management of concussion in sports and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Christopher Giza about this guideline update on evaluation and management of concussion in sports. Dr. Adam Numis is reading our e-Pearl of the week about anti -MuSK antibody myasthenia gravis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Merit Cudkowicz about her plenary session on ALS pathways to treatments. The participants had nothing to disclose except Drs. Goodkin, Giza, Numis, Espay and Cudkowicz.Dr. Goodkin serves as an editorial board member of Neurology and Surgical Neurology International; receives royalties from Up-to-Date for co-authorship of The Choking Game and other strangulation activities in children and adolescents; receives research support from the NIH.Dr. Giza serves on the data safety monitoring board for LAbiomed Institute at Harbor-UCLA Medical Center; is a consult for NHL Player's Association; serves on the speakers' bureau for the Medical Education Speakers Network; receives royalties from the publication of the book Neurological Differential Diagnosis: A prioritized approach; received funding for travel to Major League Soccer Concussion Committee meeting, California State Athletic Commission Meetings and NCAA meeting; receives research funding from NIH, UCLA faculty grants, Thrasher Research Foundation, NFL Charities, Today's and Tomorrow's Children Fund, Richie's Fund and NCAA, and gave expert testimony on several mediocolegal cases.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Cudkowicz is a consultant for TEVA Pharmaceutical Industries Ltd., Cytokinetics, Biogen Idec; receives research support from Muscular Dystrophy Association, Amyotrophic Lateral Sclerosis Association, American Telemedicine Association and the NIH.

1) Creation of the AAN Global Health Section and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. Amy Lee about her paper on the creation of the AAN Global Health Section. Dr. Adam Numis is reading our e-Pearl of the week about Tullio phenomenon. In the next part of the podcast Dr. Alberto Espay interviews Dr. Jerome Posner about receiving the 2013 President's Award at the AAN Meeting and discussing his lecture on the importance of teaching and mentoring in neurology. The participants had nothing to disclose except Drs. Mateen, Numis, Espay and Posner.Dr. Mateen has consulted for the World Health Organization, Global Polio Eradication Initiative, and Caritas.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Posner serves as an editorial board member on Up-to-Date; receives royalties from the publications of the books Diagnosis of stupor and coma and Neurologic complications of cancer; receives royalty payments, technology/inventions from Athena diagnostics.